FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311220073> ?p ?o ?g. }

• W4311220073 endingPage "328" @default.
• W4311220073 startingPage "315" @default.
• W4311220073 abstract "Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials.Adults with moderate-to-severe plaque psoriasis for ≥ 6 months were initially randomised 1:2:2 to double-blinded placebo every 2 weeks (Q2W), CZP 200 mg Q2W (loading dose of CZP 400 mg at weeks 0/2/4) or CZP 400 mg Q2W. All patients received open-label CZP (200 mg or 400 mg Q2W) from week 48. Dermatology Life Quality Index (DLQI), 36-Item Short Form Survey (SF-36), EuroQol 5-Dimensions 3-Level (EQ-5D-3L) and Work Productivity and Activity Impairment (WPAI) scores are reported as observed.At week 0, 100 patients were randomised to placebo, 186 to CZP 200 mg Q2W and 175 to CZP 400 mg Q2W. For CZP-randomised patients, 60.9% had a DLQI score of 0 or 1 by week 48. Both the physical and mental component scores of SF-36 also improved from baseline to week 48 (mean change from baseline: 4.4 and 5.4, respectively). The proportion of patients with a score of 1 in the EQ-5D-3L Pain/Discomfort dimension increased (week 0, 21.1%; week 48, 66.2%), and WPAI Presenteeism, Work Impairment, and Activity Impairment improved from baseline to week 48, with the strongest gains observed for Activity Impairment (week 0, 33.3% of time impaired; week 48, 6.7%). Across patient-reported outcomes, gains were sustained through week 144, with durable improvements observed regardless of sex, psoriatic arthritis status or prior exposure to biologics.CZP treatment was associated with sustained and tangible improvements in health-related QoL (DLQI and SF-36), health status (EQ-5D-3L) and functional impairment at work and in other daily activities (WPAI).ClinicalTrials.gov NCT02326298 (CIMPASI-1) and NCT02326272 (CIMPASI-2)." @default.
• W4311220073 created "2022-12-24" @default.
• W4311220073 creator A5025545596 @default.
• W4311220073 creator A5038505651 @default.
• W4311220073 creator A5049859852 @default.
• W4311220073 creator A5058437940 @default.
• W4311220073 creator A5061469672 @default.
• W4311220073 creator A5063878461 @default.
• W4311220073 creator A5065943846 @default.
• W4311220073 creator A5075710054 @default.
• W4311220073 creator A5080692753 @default.
• W4311220073 creator A5087192032 @default.
• W4311220073 creator A5088309041 @default.
• W4311220073 date "2022-12-13" @default.
• W4311220073 modified "2023-10-08" @default.
• W4311220073 title "Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)" @default.
• W4311220073 cites W2096991001 @default.
• W4311220073 cites W2145628010 @default.
• W4311220073 cites W2333396611 @default.
• W4311220073 cites W2346598705 @default.
• W4311220073 cites W2764022867 @default.
• W4311220073 cites W2768060890 @default.
• W4311220073 cites W2769068226 @default.
• W4311220073 cites W2797132528 @default.
• W4311220073 cites W2797238574 @default.
• W4311220073 cites W2894433258 @default.
• W4311220073 cites W2912058252 @default.
• W4311220073 cites W2916063242 @default.
• W4311220073 cites W3029751339 @default.
• W4311220073 cites W3034204123 @default.
• W4311220073 cites W3042003151 @default.
• W4311220073 cites W3174239144 @default.
• W4311220073 doi "https://doi.org/10.1007/s13555-022-00861-4" @default.
• W4311220073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36509889" @default.
• W4311220073 hasPublicationYear "2022" @default.
• W4311220073 type Work @default.
• W4311220073 citedByCount "1" @default.
• W4311220073 countsByYear W43112200732023 @default.
• W4311220073 crossrefType "journal-article" @default.
• W4311220073 hasAuthorship W4311220073A5025545596 @default.
• W4311220073 hasAuthorship W4311220073A5038505651 @default.
• W4311220073 hasAuthorship W4311220073A5049859852 @default.
• W4311220073 hasAuthorship W4311220073A5058437940 @default.
• W4311220073 hasAuthorship W4311220073A5061469672 @default.
• W4311220073 hasAuthorship W4311220073A5063878461 @default.
• W4311220073 hasAuthorship W4311220073A5065943846 @default.
• W4311220073 hasAuthorship W4311220073A5075710054 @default.
• W4311220073 hasAuthorship W4311220073A5080692753 @default.
• W4311220073 hasAuthorship W4311220073A5087192032 @default.
• W4311220073 hasAuthorship W4311220073A5088309041 @default.
• W4311220073 hasBestOaLocation W43112200731 @default.
• W4311220073 hasConcept C126322002 @default.
• W4311220073 hasConcept C142724271 @default.
• W4311220073 hasConcept C159110408 @default.
• W4311220073 hasConcept C16005928 @default.
• W4311220073 hasConcept C17991360 @default.
• W4311220073 hasConcept C1862650 @default.
• W4311220073 hasConcept C204787440 @default.
• W4311220073 hasConcept C27081682 @default.
• W4311220073 hasConcept C2776173921 @default.
• W4311220073 hasConcept C2776215756 @default.
• W4311220073 hasConcept C2777138892 @default.
• W4311220073 hasConcept C2779951463 @default.
• W4311220073 hasConcept C2780564577 @default.
• W4311220073 hasConcept C71924100 @default.
• W4311220073 hasConceptScore W4311220073C126322002 @default.
• W4311220073 hasConceptScore W4311220073C142724271 @default.
• W4311220073 hasConceptScore W4311220073C159110408 @default.
• W4311220073 hasConceptScore W4311220073C16005928 @default.
• W4311220073 hasConceptScore W4311220073C17991360 @default.
• W4311220073 hasConceptScore W4311220073C1862650 @default.
• W4311220073 hasConceptScore W4311220073C204787440 @default.
• W4311220073 hasConceptScore W4311220073C27081682 @default.
• W4311220073 hasConceptScore W4311220073C2776173921 @default.
• W4311220073 hasConceptScore W4311220073C2776215756 @default.
• W4311220073 hasConceptScore W4311220073C2777138892 @default.
• W4311220073 hasConceptScore W4311220073C2779951463 @default.
• W4311220073 hasConceptScore W4311220073C2780564577 @default.
• W4311220073 hasConceptScore W4311220073C71924100 @default.
• W4311220073 hasFunder F4320314709 @default.
• W4311220073 hasFunder F4320337846 @default.
• W4311220073 hasIssue "1" @default.
• W4311220073 hasLocation W43112200731 @default.
• W4311220073 hasLocation W43112200732 @default.
• W4311220073 hasLocation W43112200733 @default.
• W4311220073 hasOpenAccess W4311220073 @default.
• W4311220073 hasPrimaryLocation W43112200731 @default.
• W4311220073 hasRelatedWork W1978428707 @default.
• W4311220073 hasRelatedWork W2056256840 @default.
• W4311220073 hasRelatedWork W2126375175 @default.
• W4311220073 hasRelatedWork W2161648634 @default.
• W4311220073 hasRelatedWork W2461170543 @default.
• W4311220073 hasRelatedWork W2922470754 @default.
• W4311220073 hasRelatedWork W2998923669 @default.
• W4311220073 hasRelatedWork W3116349189 @default.
• W4311220073 hasRelatedWork W4245009736 @default.
• W4311220073 hasRelatedWork W4321997075 @default.
• W4311220073 hasVolume "13" @default.

• next